ClinicalTrials.gg
CompletedNCT00445939Updated Jun 27, 2011Results posted

A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease

A Phase 2/3 interventional study of adalimumab and adalimumab in Crohn's Disease, sponsored by Abbott. Completed at 18 sites in Japan. Open to participants aged 15 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-06-27.

Sponsored by Abbott · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
15 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.

Enrollment
28th of 42
90 · median 143
Started
2007
with 3 others
Phase 2/3
2 of 42
none open now
Registered
11th of 42
by date
Lead sponsor
13 of 42
Abbott

Among the 42 studies testing adalimumab in Crohn Disease, this one is the 28th largest by enrollment, is one of 4 that started in 2007, is one of 2 in phase 2/3, and was the 11th registered.

Crohn Disease

1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 15 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing adalimumab in Crohn Disease, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the efficacy and safety of adalimumab for the induction of clinical remission in Japanese subjects with Crohn's disease.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
15 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Crohn's Disease Activity Index (CDAI) score of >= 220 and \<= 450
  • If subjects have previously been administered infliximab, subjects who discontinued use due to a loss of response or intolerance to infliximab therapy

Exclusion criteria

Exclusion Criteria:

  • Ulcerative colitis or indeterminate colitis
  • History of cancer, lymphoma, leukemia or lymphoproliferative disease, active tuberculosis (TB), or (HIV)
  • Body weight is below 30 kg
  • Surgical bowel resections within the past 6 months
  • Females who are pregnant or breast-feeding or considering becoming pregnant during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Adalimumab 160 mg/80 mg

    Biological: adalimumab

  • Experimental
    Adalimumab 80 mg/40 mg

    Biological: adalimumab

  • Placebo comparator
    Placebo

    Biological: placebo

Interventions

  • Biologicaladalimumab

    160 mg at Week 0, 80 mg at Week 2

    Also known as: ABT-D2E7, Humira

  • Biologicaladalimumab

    80 mg at Week 0, 40 mg at Week 2

    Also known as: ABT-D2E7, Humira

  • Biologicalplacebo

    Placebo at Week 0 and Week 2

06

What researchers measure

Primary outcomes

  1. The Number of Subjects With a Clinical Remission (Crohn's Disease Activity Index [CDAI] < 150) at Week 4

    CDAI is used to quantify the symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Comparison of the number of subjects with a clinical remission (CDAI \< 150) in the adalimumab 160 mg (Week 0)/ 80 mg (Week 2) and adalimumab 80 mg (Week 0)/ 40 mg (Week 2) groups at Week 4.

    Time frame: 4 Weeks

Secondary outcomes

  1. Clinical Remission (CDAI < 150) at Week 2

    Number of subjects in each treatment group in clinical remission (CDAI \< 150) in Full Analysis Set (FAS) using non-responder Imputation (NRI) at Week 2.

    Time frame: Week 2

  2. Clinical Response (CR-70 and CR-100) in Period A

    The number of subjects in each treatment group with a clinical response 70 (CDAI decrease of \>=70 compared to Baseline) and 100 (CDAI decrease of \>=100 compared to Baseline) at Week 2 and Week 4.

    Time frame: Weeks 2 and Week 4

  3. Clinical Response (CR-70 and CR-100) in Period B

    The Number of subjects in each treatment group with a CR-70 (CDAI decrease of \>= 70 compared to Baseline) and 100 (CDAI decrease of \>= 100 compared to Baseline) in subjects who were non-responders at Week 4 at Week 6 and Week 8.

    Time frame: Week 6 and Week 8

  4. Clinical Remission (CDAI <150) at Week 6 and Week 8

    The number of subjects with clinical remission (CDAI \< 150) in the subjects who were non-responders at Week 4 calculated with non-responder imputation (NRI) at Week 6 and Week 8

    Time frame: Week 6 and Week 8

07

Results

Posted Mar 23, 2009
Limitations and caveats
Small population, therefore no statistical tests were performed

Participant flow

Subjects with moderate to severe Crohn's Disease (Crohn's Disease Activity Index \[CDAI\] \>= 220 and \<= 450) were enrolled into study. The period from the first dose of study drug to the evaluation at Week 4 is Period A. The period from the study drug injection at Week 4 to the evaluation at Week 8 is Period B.

Period A - Week 0 - Week 4
Participant flow — Period A - Week 0 - Week 4
MilestoneAdalimumab 160 mg/80 mgAdalimumab 80 mg/40 mgPlaceboAdalimumab 40mg /40 mg
Started3334230
Completed3232230
Not completed1200
Withdrew: Adverse event1200
Period B - Week 4 - Week 8
Participant flow — Period B - Week 4 - Week 8
MilestoneAdalimumab 160 mg/80 mgAdalimumab 80 mg/40 mgPlaceboAdalimumab 40mg /40 mg
Started160021
Completed140020
Not completed2001
Withdrew: Adverse event2001

Outcome measures

PrimaryThe Number of Subjects With a Clinical Remission (Crohn's Disease Activity Index [CDAI] < 150) at Week 4

CDAI is used to quantify the symptoms of patients with Crohn's Disease. A score below 150 indicates remission and a score above 450 indicates severe disease. Comparison of the number of subjects with a clinical remission (CDAI \< 150) in the adalimumab 160 mg (Week 0)/ 80 mg (Week 2) and adalimumab 80 mg (Week 0)/ 40 mg (Week 2) groups at Week 4.

Time frame:
4 Weeks
Reported as:
Number · Particpants
The Number of Subjects With a Clinical Remission (Crohn's Disease Activity Index [CDAI] < 150) at Week 4
ParticpantsAdalimumab 160 mg/80 mgAdalimumab 80 mg/40 mgPlacebo
The Number of Subjects With a Clinical Remission (Crohn's Disease Activity Index [CDAI] < 150) at Week 41163
SecondaryClinical Remission (CDAI < 150) at Week 2

Number of subjects in each treatment group in clinical remission (CDAI \< 150) in Full Analysis Set (FAS) using non-responder Imputation (NRI) at Week 2.

Time frame:
Week 2
Reported as:
Number · Participants
Clinical Remission (CDAI < 150) at Week 2
ParticipantsAdaliumab 160 mg/80 mgAdalimumab 80 mg/40 mgPlacebo + 160/80 mg
Week 2651
SecondaryClinical Response (CR-70 and CR-100) in Period A

The number of subjects in each treatment group with a clinical response 70 (CDAI decrease of \>=70 compared to Baseline) and 100 (CDAI decrease of \>=100 compared to Baseline) at Week 2 and Week 4.

Time frame:
Weeks 2 and Week 4
Reported as:
Number · participants
Clinical Response (CR-70 and CR-100) in Period A
participantsAdaliumab 160 mg/80 mgAdalimumab 80 mg/40 mgPlacebo
CR-70 at Week 215174
CR-70 at Week 423207
CR-100 at Week 210112
CR-100 at Week 415174
SecondaryClinical Response (CR-70 and CR-100) in Period B

The Number of subjects in each treatment group with a CR-70 (CDAI decrease of \>= 70 compared to Baseline) and 100 (CDAI decrease of \>= 100 compared to Baseline) in subjects who were non-responders at Week 4 at Week 6 and Week 8.

Time frame:
Week 6 and Week 8
Reported as:
Number · Participants
Clinical Response (CR-70 and CR-100) in Period B
ParticipantsAdaliumab 160 mg/80 mg + 40/40 mgAdalimumab 80 mg/40 mg + 40/40 mgPlacebo + Adalimumab 160/80 mg
CR-70 at Week 6149
CR-70 at Week 83512
CR-100 at Week 6013
CR-100 at Week 8027
SecondaryClinical Remission (CDAI <150) at Week 6 and Week 8

The number of subjects with clinical remission (CDAI \< 150) in the subjects who were non-responders at Week 4 calculated with non-responder imputation (NRI) at Week 6 and Week 8

Time frame:
Week 6 and Week 8
Reported as:
Number · Participants
Clinical Remission (CDAI <150) at Week 6 and Week 8
ParticipantsAdaliumab 160 mg/80 mg + 40/40 mgAdalimumab 80 mg/40 mg + 40/40 mgPlacebo + Adalimumab 160/80 mg
Clinical Remission at Week 6012
Clinical Remission at Week 8012

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adaliumab 160 mg/80 mg———
Adalimumab 80 mg/40 mg———
Placebo———
Adalimumab 160 mg/80 mg + 40/40 mg———
80/40 mg + 40/40 mg———
Placebo + Adalimumab 160/80 mg———
Most frequent serious events
Most frequent serious events
EventAdaliumab 160 mg/80 mgAdalimumab 80 mg/40 mgPlaceboAdalimumab 160 mg/80 mg + 40/40 mg80/40 mg + 40/40 mgPlacebo + Adalimumab 160/80 mg
Crohn's DiseaseGastrointestinal disorders0/332/342/231/91/120/16
EpididymitisReproductive system and breast disorders1/330/340/230/90/120/16
Abdominal abcessInfections and infestations0/331/340/230/90/120/16
C-reactive protein increased (at investigator's discretion)Investigations0/331/340/230/90/120/16
SubileusGastrointestinal disorders0/331/340/230/90/120/16
Most frequent other events
Showing 10 of 40
Most frequent other events
EventAdaliumab 160 mg/80 mgAdalimumab 80 mg/40 mgPlaceboAdalimumab 160 mg/80 mg + 40/40 mg80/40 mg + 40/40 mgPlacebo + Adalimumab 160/80 mg
NasopharyngitisInfections and infestations0/331/340/231/91/123/16
HeadacheNervous system disorders3/330/341/230/92/121/16
NauseaGastrointestinal disorders1/331/343/230/90/120/16
Adverse drug reactionGeneral disorders1/331/341/231/90/120/16
Application site swellingGeneral disorders0/330/340/231/90/120/16
Blood creatine phosphokinase (at investigator's discretion)Investigations0/331/340/231/90/120/16
Chest painGeneral disorders0/330/340/231/90/120/16
Feeling abnormalGeneral disorders0/330/340/231/90/120/16
HypoglycaemiaMetabolism and nutrition disorders0/330/340/231/90/120/16
Instillation site painGeneral disorders0/330/340/231/90/120/16

Baseline characteristics

Age Continuous
Age Continuous(years)Adalimumab 160 mg/80 mgAdalimumab 80 mg/40 mgPlaceboTotal
Mean32.0 ± 9.6030.6 ± 9.2630.4 ± 6.9331.1 ± 8.80
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab 160 mg/80 mgAdalimumab 80 mg/40 mgPlaceboTotal
Female1318738
Male20161652
Region of Enrollment
Region of Enrollment(participants)Adalimumab 160 mg/80 mgAdalimumab 80 mg/40 mgPlaceboTotal
Japan33342390
08

Study locations

18 sites
  • Aichi, Japan
  • Chiba, Japan
  • Ehime, Japan
  • Fukuoka, Japan
  • Hiroshima, Japan
  • Hokkaido, Japan
  • Hyogo, Japan
  • Kagawa, Japan
  • Kanagawa, Japan
  • Kochi, Japan
  • Kyoto, Japan
  • Miyagi, Japan
  • Okayama, Japan
  • Okinawa, Japan
  • Osaka, Japan
  • Shiga, Japan
  • Shizuoka, Japan
  • Tokyo, Japan
09

References and documents

Publications

  • Watanabe M, Hibi T, Lomax KG, Paulson SK, Chao J, Alam MS, Camez A; Study Investigators. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohns Colitis. 2012 Mar;6(2):160-73. doi: 10.1016/j.crohns.2011.07.013. Epub 2011 Aug 26. PubMed 22325170 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007 and a primary completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2009, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2007
First posted
Mar 9, 2007
Start
Feb 2007
Primary completionActual
Dec 2007
Results first posted
Mar 23, 2009
Last update
Jun 27, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00445939
Lead sponsor
Abbott
Collaborators
Abbott Japan Co.,Ltd, Eisai Co., Ltd.
First posted
Mar 9, 2007
Start date
Feb 2007
Primary completion
Dec 2007
Results posted
Mar 23, 2009
Last update
Jun 27, 2011

Study contacts

Morio Ozawa
study director · Abbott Japan Co.,Ltd
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion